Communiqués Ligand Pharmaceuticals Incorporated

Actions

LGND

US53220K5048

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 20:07:13 29/07/2026			Varia. 5j.	Varia. 1 janv.
289,83 ^USD	-2,18%		-4,91%	+53,02%

15/07	LIGAND PHARMACEUTICALS INCORPORATED : RBC Capital Markets favorable sur le dossier	ZM
14/07	Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) a finalisé l'acquisition de XOMA Royalty Corporation (NasdaqGM:XOMA) auprès d'un groupe d'actionnaires.	CI

Communiqués

23/07	Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026	AQ
14/07	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets	GL
14/07	XOMA Royalty Announces Closing of Its Acquisition by Ligand	AQ
14/07	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets	AQ
30/06	Zerion Pharma completes royalty financing and equity investment transaction with Ligand to advance the Dispersome® technology	AQ
25/06	Ligand Announces Closing of Convertible Senior Notes Offering	AQ
23/06	Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering	AQ
22/06	Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031	AQ
10/06	Ligand Announces 2026 Investor Day in New York City	AQ
27/05	Ligand to Participate in June Investor Conferences	AQ
07/05	Ligand Pharmaceuticals Incorporated : First Quarter 2026 Earnings Webcast	PU
07/05	Ligand: Q1 Earnings Snapshot	AQ
07/05	Ligand Reports First Quarter 2026 Financial Results	AQ
05/05	Ligand to Participate in May Investor Conferences	AQ
27/04	Ligand Pharmaceuticals Incorporated : To Acquire XOMA Royalty	PU
27/04	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	AQ
22/04	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026	AQ
15/04	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI in FSGS	AQ
26/03	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team	AQ
04/03	Ligand to Participate in March Investor Conferences	AQ
26/02	Ligand: Q4 Earnings Snapshot	AQ
26/02	Ligand Pharmaceuticals Incorporated : Fourth Quarter 2025 Earnings Webcast	PU
26/02	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
12/02	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	AQ
04/02	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ